USPTO serial 79452038
Reviewed by CopyMark Law Group
The USPTO has issued an Office Action on this application. A response is typically required before the deadline, or the application can be abandoned.
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; pharmaceutical preparations for treating diabetes; pharmaceutical preparations for peripheral nervous system; pharmaceutical preparations used in organ transplantation; pharmaceutical preparations for the central nervous system; pharmaceutical preparations for the treatment of infectious diseases; pharmaceutical preparations for the treatment of eye diseases and conditions; radioactive pharmaceutical preparations for use in vivo diagnostic or therapeutic use | ACTIVE | — |
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
| Date | Code | Event | What it means |
|---|---|---|---|
| Jun 26, 2026 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Jun 25, 2026 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 25, 2026 | DOCK | ASSIGNED TO EXAMINER | — |
| Jun 24, 2026 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Jun 24, 2026 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jun 22, 2026 | LIMI | LIMITATION FROM ORIGINAL APPLICATION ENTERED | — |
| Jun 18, 2026 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |